SavedAdd your journal

Journals / Tüberküloz ve Toraks / 2021 / Cilt: 69 - Sayı: 2

COVID-19 and thrombosis: Prophylaxis and management

COVID-19 ve tromboz: Profilaksi ve yönetimi

Bengü ŞAYLAN
Tayfun ÇALIŞKAN
Kadir CANOĞLU
Pages
269–278
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thromboprophylaxis is recommended in patients with COVID-19 to prevent arterial and venous thromboembolism.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:COVID-19 emerged in Wuhan, China in late December 2019, and WHO declared it a pandemic on March 11, 2020.
📊
Key Findings & Data:There have been over 83.9 million cases with 1.8 million deaths worldwide.
💡
Conclusion & Impact:Thromboprophylaxis is recommended in patients with COVID-19 to prevent arterial and venous thromboembolism.
🔬Design:Review & Systematic Survey
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

COVID-19 emerged in Wuhan, China in late December 2019, and WHO declared it a pandemic on March 11, 2020. The disease has a wide spectrum ranging from asymptomatic or mild disease to ARDS and death. There have been over 83.9 million cases with 1.8 million deaths worldwide. COVIDassociated coagulopathy appears to be an entity responsible for deaths. Thromboprophylaxis is recommended in patients with COVID-19 to prevent arterial and venous thromboembolism. Low molecular weight heparin such as enoxaparin is often recommended. However, there is still no consensus regarding the treatment dose and duration. The purpose of this review was to observe the pathogenesis of thromboembolic events in COVID-19, current thromboprophylaxis regimens, treatment dosage and duration with guidelines of international scientific institutions.

Özet

COVID-19 ilk olarak Çin’in Wuhan kentinde ortaya çıkmış ve 11 Mart 2020 tarihinde WHO pandemi ilan etmiştir. Asemptomatik ya da hafif hastalıktan ARDS ve ölüme kadar gidebilen geniş bir yelpazeye sahiptir. Tüm dünyada 83,9 milyon vaka ile birlikte 1,8 milyondan fazla ölüm görülmüştür. COVID’e bağlı koagülapati ölümlerden sorumlu antite olarak görülmektedir. COVID-19 hastalarında arteriyel ve venöz tromboemboliyi önlemek için tromboprofilaksi önerilmektedir. Genellikle enoksaparin gibi düşük molükül ağırlıklı heparin önerilmektedir. Ancak, hala tedavi süresi ve dozu ile ilgili ortak görüş bulunmamaktadır. Bu derlemenin amacı, COVID-19’da tromboembolik olayların patogenezi, uluslararası rehberlerin güncel profilaksi önerileri, dozaj ve sürelerini incelemektir

🔖

Cite This Article

ŞAYLAN, B., ÇALIŞKAN, T., CANOĞLU, K. (2022). COVID-19 and thrombosis: Prophylaxis and management. Tüberküloz ve Toraks, Cilt: 69 - Sayı: 2, 269–278. https://ajindex.com/articles/618300

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. World Health Organization (WHO). WHO DirectorGeneral’s opening remarks at the media briefing on COVID-19. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11- march-2020 (Accessed date: 5 Jan 2021)
  2. Barek MA, Aziz MA, Islam MS. Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID19 cases: A meta-analysis with 55 studies and 10014 cases. Heliyon 2020; 6(12): e05684
  3. World Health Organization (WHO). WHO Coronavirus Disease (COVID-19) Dashboard. Available from: https:// covid19.who.int/ (Accessed date: 5 Jan 2021)
  4. Marongiu F, Grandone E, Barcellona D. Pulmonary thrombosis in 2019-nCoV pneumonia? J Thromb Haemost 2020; 18(6): 1511-13
  5. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med 2020; 383(2): 120-8
  6. Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: A Prospective Cohort Study. Ann Intern Med 2020; 173(4): 268-77
  7. World Health Organization (WHO). Clinical management of COVID-19 interim guidance. Available from: https:// www.who.int/publications/i/item/clinical-management-of-covid-19 (Accessed date: 6 Jan 2021)
  8. Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol 2020; 20(5): 269-70
  9. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020; 71(15): 762-8
  10. Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020; 18(7): 1738-42
  11. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18(4): 844-7
  12. Boonyawat K, Chantrathammachart P, Numthavaj P, Nanthatanti N, Phusanti S, Phuphuakrat A, et al. Incidence of thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Thromb J 2020; 18(1): 34
  13. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in